Lead Product(s): Viltolarsen
Therapeutic Area: Genetic Disease Product Name: Viltepso
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: NS PHARMA INC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 02, 2020
Option Care Health has been selected to participate in the limited distribution network of VILTEPSO™ (viltolarsen) for patients with Duchenne Muscular Dystrophy (“DMD”) who are amenable to exon 53 skipping therapy.